Thursday, 20 December 2012
Aesica looks for new API processes
Aesica has partnered with Durham and Leeds Universities to identify and commercialise alternative technologies for API manufacturing processes. The partnership is supported by the METRC Innovation Award that supports new research between universities and companies in the fields of nanotechnology, science and engineering.
Contract Pharma
Ampac revenues rise
Ampac's fine chemical segment reported FY12 revenues of $111.5m up 25% on 2011. The company attributed this improvement to a recovery from a lag in antiviral product sales in 2011 and to growth from existing or new products.
Seeking Alpha
IGIG acquires Tessenderlo sites
International Chemical Investors Group has acquired the pharmaceutical ingredients activities of Tessenderlo. ICIG has acquired the facilities in Calaire, France, and Farchemia, Italy, to International Chemical Investors Group (ICIG), a private industrial holding company for an undisclosed sum.
In-pharma Technologist
Genmab desperate to sell
Genmab has reduced the fair value of the Brooklyn Park, MN, facility it has been trying to sell for the last few years from $58m to zero. The company will now enter into an aggressive sales process with the aim of closing a transaction in Q1 2013.
Pharma Bio Source
MHRA to seek API details
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) will soon contact UK-based marketing authorisation holders to request data on APIs imported into the UK to ensure they are manufactured in accordance with the EU GMP or, if imported into the EU, with equivalent rules. The MHRA recently said that almost 1200 API plants may require inspection to meet the EU rules.
MHRA
Thursday, 6 December 2012
Wednesday, 5 December 2012
Isochem acquires Wychem
Isochem has acquired kg-scale fine chemical intermediate supplier Wychem. Isochem said the acquisition allows it to offer customers continuity of service and capacities ranging from the kilogram to a hundred metric tons.
Isochem
Dottikon sales and losses increase in H1
Dottikon's first half 2012/13 sales increased 22% to CHF37.7m. However, the company said its production output fell 9% due to unexpected delays in projects and products. Dottikon reported a loss of CHF4.0m for the period.
Dottikon
Hovione drug solubility collaboration with Solvias
Hovione will combine its drug delivery expertise with Solvias' solid state chemistry capabilities in a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. Hovione will use Solvias’ co-crystallisation expertise and crystal design solutions to overcome poor bioavailability and other drug delivery challenges.
Hovione
